Halozyme Therapeutics, Inc. (NASDAQ:HALO)

CAPS Rating: 2 out of 5

A biopharmaceutical company dedicated to the development and commercialization of recombinant human enzymes for the drug delivery, palliative care, oncology and infertility markets.

Recs

0
Player Avatar Tri3 (< 20) Submitted: 11/1/2008 9:34:36 AM : Outperform Start Price: $4.76 HALO Score: +34.68

+

Featured Broker Partners


Advertisement